ReviewWorld journal of gastroenterology2012
Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.
Review in World journal of gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 3 syntheses or guidelines pooled it, 181 citations in OpenAlex.
- Clinical Practice Guidelines for Liver Transplantation in Saudi Arabia.Saudi medical journal · 2021Guideline
- Guideline
- ACG Clinical Guideline: Primary Sclerosing Cholangitis.The American journal of gastroenterology · 2015Guideline
- Long-term Follow-up After Hypothermic Oxygenated Machine Perfusion in DCD Liver Transplantation: Results of a Randomized Controlled Multicenter Trial (DHOPE-DCD).Annals of surgery · 2025Trial
- Fibrosis in One-Year Protocol Biopsies After Liver Transplantation Is Associated With Graft Loss: A Multicenter Cohort Study.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- State-Level Geographic Disparities in Liver Transplant Access: Waitlist Outcome Patterns.Journal of clinical medicine · 2026Article
- Cultured bacteria isolated from primary sclerosing cholangitis patient bile induce inflammation and cell death.mSphere · 2025Article
- Clinical outcomes of liver transplantation in Caroli syndrome: a retrospective analysis.Orphanet journal of rare diseases · 2025Article
- The 2024 diagnostic criteria for primary sclerosing cholangitis.Journal of gastroenterology · 2025Review
- [Are antibiotics immunomodulators? An attempt to use vancomycin in the treatment of primary sclerosing cholangitis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Primary sclerosing cholangitis.Nature reviews. Disease primers · 2025Review
- CDC42: unlocking a novel therapeutic target for primary sclerosing cholangitis through Mendelian randomization.American journal of translational research · 2025Article
- Risk Factors for Recurrence of Primary Sclerosing Cholangitis after Liver Transplantation: Single-Center Data.Journal of personalized medicine · 2024Article
- Liver transplantation for primary sclerosing cholangitis-morbidities including disease recurrence.Hepatobiliary surgery and nutrition · 2024Article
- Panic at the Bile Duct: How Intrahepatic Cholangiocytes Respond to Stress and Injury.The American journal of pathology · 2023Review
- Impact of Inflammatory Bowel Disease Subtypes on the Post-liver Transplant Outcomes of Patients with Primary Sclerosing Cholangitis.Digestive diseases and sciences · 2023Article
- Liver transplant in primary sclerosing cholangitis: Current trends and future directions.World journal of hepatology · 2023Review
- Main factors influencing long-term outcomes of liver transplantation in 2022.World journal of hepatology · 2023Review
- Expression of unfolded protein response genes in post-transplantation liver biopsies.BMC gastroenterology · 2022Article
- Changes in beta-catenin expression and activation during progression of primary sclerosing cholangitis predict disease recurrence.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary sclerosing cholangitis (PSC) is a chronic progressive inflammatory disease affecting the bile ducts, leading to fibrosis and eventually cirrhosis in most patients. Its etiology is unknown and so far no effective medical therapy is available. Liver transplantation (LTX) is the only curative treatment and at present PSC is the main indication for LTX in the Scandinavian countries. Close to half of the PSC patients experience one or more episodes of acute cellular rejection (ACR) following transplantation and approximately 1/5 of the transplanted patients develop recurrent disease in the graft. In addition, some reports indicate that ACR early after LTX for PSC can influence the risk for recurrent disease. For these important post-transplantation entities affecting PSC patients, we have reviewed the current literature on epidemiology, pathogenesis, treatment and the possible influence of rejection on the risk of recurrent disease in the allograft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.